Halozyme Therapeutics, Inc. (HALO) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) from a sell rating to a hold rating in a report released on Tuesday, Analyst Ratings.Net reports.
According to Zacks, “Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company’s broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme’s highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. “
HALO has been the topic of several other research reports. Wells Fargo assumed coverage on Halozyme Therapeutics in a research note on Friday, December 4th. They set an outperform rating on the stock. Barclays dropped their price target on Halozyme Therapeutics from $27.00 to $16.00 and set an overweight rating on the stock in a research note on Wednesday, February 24th. Canaccord Genuity started coverage on Halozyme Therapeutics in a research note on Monday, February 1st. They issued a buy rating and a $10.00 price target on the stock. JMP Securities dropped their price target on Halozyme Therapeutics from $22.00 to $20.00 and set a market outperform rating on the stock in a research note on Wednesday, March 9th. Finally, Citigroup Inc. started coverage on Halozyme Therapeutics in a research note on Wednesday, November 18th. They issued a buy rating and a $25.00 price target on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Halozyme Therapeutics presently has an average rating of Buy and an average price target of $19.78.
Several institutional investors recently made changes to their positions in the stock. Woodstock bought a new position in shares of Halozyme Therapeutics during the fourth quarter valued at $503,000. DekaBank Deutsche Girozentrale boosted its position in Halozyme Therapeutics by 1.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 65,000 shares of the biopharmaceutical company’s stock worth $1,132,000 after buying an additional 1,000 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Halozyme Therapeutics by 11.3% in the fourth quarter. Ameriprise Financial Inc. now owns 69,422 shares of the biopharmaceutical company’s stock worth $1,203,000 after buying an additional 7,071 shares during the last quarter. Nationwide Fund Advisors boosted its position in Halozyme Therapeutics by 2.3% in the fourth quarter. Nationwide Fund Advisors now owns 69,817 shares of the biopharmaceutical company’s stock worth $1,210,000 after buying an additional 1,563 shares during the last quarter. Finally, ClariVest Asset Management LLC boosted its position in Halozyme Therapeutics by 64.9% in the fourth quarter. ClariVest Asset Management LLC now owns 75,830 shares of the biopharmaceutical company’s stock worth $1,314,000 after buying an additional 29,839 shares during the last quarter.
Halozyme Therapeutics (NASDAQ:HALO) opened at 8.39 on Tuesday. The firm’s market cap is $1.08 billion. The company’s 50 day moving average price is $8.34 and its 200 day moving average price is $13.64. Halozyme Therapeutics has a 52-week low of $6.96 and a 52-week high of $25.25.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, February 29th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.11. The business had revenue of $52.20 million for the quarter, compared to analyst estimates of $37.06 million. The business’s quarterly revenue was up 71.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. Analysts predict that Halozyme Therapeutics will post ($1.00) earnings per share for the current fiscal year.
Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.

Source:WKRB News and Analysis

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.

Online Privacy Policy Only

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.

DISCLAIMER

This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.